Ambryon Biosciences

Staphylococcus aureus Cas9 (SaCas9)

RNA-guided DNA endonuclease from Staphylococcus aureus that cleaves double-stranded DNA at sites specified by a 21- to 23-nucleotide guide sequence, requiring an NNGRRT PAM immediately 3' of the target. At 1,053 amino acids it packages together with its guide RNA inside a single AAV vector, which SpCas9 does not.

OriginStaphylococcus aureus type II CRISPR-Cas system
Sequence HashA3f8a175c8abdbbad982e83ba5d53434e7dd01fe653af87a3ef3f62b5da9e153
Features[]
Cut TypeBlunt
Pam SequenceNNGRRT

Characteristics

Cleaves both strands of the target three base pairs upstream of the PAM to produce a blunt double-strand break; the RuvC-like domain cuts the noncomplementary strand and the HNH domain cuts the strand complementary to the guide, while a separate PAM-interacting domain reads the NNGRRT motif. Guide spacers of 20 to 24 nucleotides give maximal activity, 18 and 19 nucleotides retain partial activity, and 17 nucleotides or shorter are inactive. At genomic sites carrying NGGRRT PAMs, which both SaCas9 and SpCas9 accept, the two enzymes produce indels at comparable rates. D10A inactivates RuvC and N580A inactivates HNH, each converting the 1,053-residue protein into a nickase; paired D10A nickases with guide offsets of 0 to 125 base pairs reach indel frequencies near 60% in HEK293 cells.

Applications

Validated for single-AAV in vivo editing. An AAV8 vector carrying SaCas9 and a Pcsk9 guide, injected intravenously in mice at 2 × 10¹¹ genome copies, produces over 40% indels in liver within one week, a ~95% fall in serum Pcsk9 and a ~40% fall in total cholesterol. AAV-delivered SaCas9 excises dystrophin exon 23 in mdx mice and restores dystrophin in skeletal and cardiac muscle. EDIT-101 pairs SaCas9 with two CEP290 guides in AAV5 for subretinal injection in Leber congenital amaurosis type 10.

Limitations

The NNGRRT PAM is more restrictive than the NGG PAM of SpCas9; the KKH variant (E782K/N968K/R1015H) relaxes recognition to NNNRRT and roughly doubles the number of targetable sites. Guide spacers of 17 nucleotides or shorter are inactive. Anti-SaCas9 antibodies occur in 78% of healthy adult donors and anti-SaCas9 T cells in 78%, a risk for in vivo therapeutic delivery.

Sequence3,282 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Kleinstiver et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nat Biotechnol — Kleinstiver 2015 SaCas9-KKH
  2. 2.Ran et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature — Ran 2015 SaCas9
  3. 3.Friedland et al. (2015). Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol — Friedland 2015 SaCas9

Identifiers & revision